Optical Coherence Tomography of Airway and Pleural Disorders

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Beckman Laser Institute University of California Irvine
Chao Family Comprehensive Cancer Center,UCIMC
Information provided by (Responsible Party):
Beckman Laser Institute and Medical Center, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00580892
First received: December 20, 2007
Last updated: January 14, 2015
Last verified: January 2015
  Purpose

The researcher can use Optical coherence tomography a near-infrared diode to emit light that can produce images of the specimen under investigation and provide information about tissue abnormalities without causing damage.


Condition Intervention
Disorder of Pleura and Pleural Cavity
Device: Optical Coherence Tomography imaging

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Optical Coherence Tomography of Airway and Pleural Disorders

Resource links provided by NLM:


Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • histopathology [ Time Frame: up to 4 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 170
Study Start Date: July 2007
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Airway and Pleural Disorders
Optical Coherence Tomography imaging
Device: Optical Coherence Tomography imaging
Optical Coherence Tomography imaging

Detailed Description:

The researcher can use Optical coherence tomography endoscopic imaging to improve diagnosis and treatment of airway and pleural malignancy. In the events of burn injury and smoke inhalation injury, the Optical coherence tomography can determine the change of the airway tissues and severity of airway injury.

During endoscopic procedure the lesions will be biopsied and prepared by standard histologic methods. The Optical coherence tomography endoscopic imaging can measured histologic of the tissue samples and compared to standard histologic examination. The Optical coherence tomography endoscopic imaging can measured the epithelial thickness and compared to visual inspection of the mucosa on bronchoscopy.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Study population will be selcted from University of California Irvine Chao Cancer Center.

Criteria

Inclusion Criteria:

  • Adult 18 or older, male or female.
  • Plans for bronchoscopic with possible biopsy procedures.

Exclusion Criteria:

  • Age less than 18 years of age
  • Not plan for bronchoscopic with possible biopsy procedures.
  • Pregnant or breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00580892

Locations
United States, California
Pulmonary and Critical Care Medicine
Irvine, California, United States, 92612
Sponsors and Collaborators
University of California, Irvine
Beckman Laser Institute University of California Irvine
Chao Family Comprehensive Cancer Center,UCIMC
Investigators
Principal Investigator: Matthew Brenner, M.D Beckman Laser Institute
  More Information

No publications provided

Responsible Party: Beckman Laser Institute and Medical Center, Principal Investigator, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00580892     History of Changes
Other Study ID Numbers: NIH/LAMMP-2006-4982
Study First Received: December 20, 2007
Last Updated: January 14, 2015
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on March 26, 2015